Pangen Biotech Inc.
222110
企業サマリー
四半期業績の推移
売上
営業利益率
市場選好度
※ グラフをクリックすると、該当月のAI分析情報が表示されます。
売上
連結
個別
営業利益
連結
個別
当期純利益
連結
個別
財務情報
Excel保存
該当期間の財務情報データがありません。
~
四半期
決算
*単位基準で小数点第4位以下の値は「0/-0」と表記されます
財務指標予測
※ 本予測値は過去データに基づくAIの単純な推定値であり、実際の実績とは異なる場合があります。
企業概要
2026年6月 時点
Pangen Biotech Inc. built GMP facilities for biopharmaceutical production from its early days, and using these GMP facilities together with its proprietary PanGen CHO-TECH(TM) technology and biopharmaceutical commercialization technology, the company carries out the following businesses: the production and sale of the biosimilar EPO drug; contract manufacturing (CMO) and development technology transfer services (CDO) for biopharmaceuticals, including non-clinical and clinical samples; and biopharmaceutical development. Biosimilar drug production and sale business: EPO drug, an anemia treatment for chronic renal failure patients. Biopharmaceutical CMO and development technology transfer (CDO) business: CDMO (Contract Development and Manufacturing Organization). Biopharmaceutical development business: Factor VIII, a treatment for hemophilia A; Aflibercept, a treatment for macular degeneration and macular edema; an anti-SFTSV antibody treatment for severe fever with thrombocytopenia syndrome; and G-CSF, an adjuvant for cancer treatment. The biosimilar EPO drug, an anemia treatment for chronic renal failure patients that the company successfully developed on its own, received marketing authorization under the product name Erysaa from the Malaysian health authority in January 2019 and has been sold in the Malaysian market since March 2019; it received marketing authorization under the product name Panpotin in Korea in November 2019 and domestic sales began in February 2020; in the Philippines it received marketing authorization for 4000 IU (product name Erysaa) in August 2022 and for 2000 IU (product name Erysaa) in October 2022, and has been sold there since December 2022; and in Saudi Arabia it obtained marketing authorization (product name: Panpotin) in May 2023 and has been sold there since March 2024.
代表理事
Yoon Jaeseung
設立日
2010年1月29日
法人区分
KOSDAQ
産業分類
Manufacture of medicaments
法人登録番号
13111-0248194
事業者登録番号
129-86-42227
電話番号
031-733-9165
FAX番号
031-733-9167
ウェブサイト
www.pangen.com
会社住所
306 Sinwon-ro, Yeongtong-gu, Suwon-si, Gyeonggi-do
製品およびサービス
コメント